國立高雄大學圖資館 |

語系: 繁體中文

說明(常見問題)

圖資館首頁

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

New rapid-acting antidepressants

Hashimoto, Kenji.

New rapid-acting antidepressants

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	New rapid-acting antidepressantsedited by Kenji Hashimoto, Mario Manto.
其他作者:	Hashimoto, Kenji.
出版者:	Cham :Springer International Publishing :2021.
面頁冊數:	vii, 149 p. :ill., digital ;24 cm.
Contained By:	Springer Nature eBook
標題:	Antidepressants.
電子資源:	https://doi.org/10.1007/978-3-030-79790-4
ISBN:	9783030797904$q(electronic bk.)

New rapid-acting antidepressants
New rapid-acting antidepressants[electronic resource] /edited by Kenji Hashimoto, Mario Manto. - Cham :Springer International Publishing :2021. - vii, 149 p. :ill., digital ;24 cm. - Contemporary clinical neuroscience,2627-5341. - Contemporary clinical neuroscience..

(R)-ketamine: A new rapid-acting antidepressant -- (2R,6R)-hydroxynorketamine, a metabolite of ketamine: the antidepressant actions and the mechanisms -- Predictable biomarkers for rapid-acting antidepressant response to ketamine -- Nitrous Oxide: an old compound with emerging psychotropic properties -- Novel AMPA receptor potentiators TAK-137 and TAK-653 as potential rapid-acting antidepressants -- AMPA receptor potentiators as potential rapid-acting antidepressants -- mGlu2/3 receptor antagonists as rapid-acting antidepressants -- Antidepressant effects of the muscarinic receptor antagonist scopolamine: Clinical and preclinical review.

This book discusses new candidates for rapid-acting antidepressants, such as (R)-ketamine, (2R,6R)-hydroxynorketamine, scopolamine, mGluR2/3 antagonists and AMPA receptor agonists. There are serious limitations to currently available antidepressants, such as delayed onset and low rates of efficacy. The discovery that a single dose of ketamine, an NMDAR antagonist, can produce rapid antidepressant effects that are sustained has led to new research in this area. In this volume, a variety of novel pharmaceutical treatments are examined. This volume would be useful to both researchers and clinicians who work in the field of pharmacology, specifically CNS drug treatments. Discusses new candidate for rapid-acting antidepressants Provides information for those who work in the field of CNS drugs Ideal for pharmacologists, psychiatrists, and those who want to learn about CNS drugs at the graduate level.

ISBN: 9783030797904$q(electronic bk.)

Standard No.: 10.1007/978-3-030-79790-4doiSubjects--Topical Terms:

252255
Antidepressants.

LC Class. No.: RM332

Dewey Class. No.: 616.8527061

New rapid-acting antidepressants
LDR:02591nmm a2200337 a 4500 001 610354
003 DE-He213
005 20211022124140.0
006 m d
007 cr nn 008maaau
008 220330s2021 sz s 0 eng d
020 $a 9783030797904$q(electronic bk.)
020 $a 9783030797898$q(paper)
024 7 $a 10.1007/978-3-030-79790-4 $2 doi
035 $a 978-3-030-79790-4
040 $a GP $c GP
041 0 $a eng
050 4 $a RM332
072 7 $a PSAN $2 bicssc
072 7 $a MED057000 $2 bisacsh
072 7 $a PSAN $2 thema
082 0 4 $a 616.8527061 $2 23
090 $a RM332 $b .N532 2021
245 0 0 $a New rapid-acting antidepressants $h [electronic resource] / $c edited by Kenji Hashimoto, Mario Manto.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2021.
300 $a vii, 149 p. : $b ill., digital ; $c 24 cm.
490 1 $a Contemporary clinical neuroscience, $x 2627-5341
505 0 $a (R)-ketamine: A new rapid-acting antidepressant -- (2R,6R)-hydroxynorketamine, a metabolite of ketamine: the antidepressant actions and the mechanisms -- Predictable biomarkers for rapid-acting antidepressant response to ketamine -- Nitrous Oxide: an old compound with emerging psychotropic properties -- Novel AMPA receptor potentiators TAK-137 and TAK-653 as potential rapid-acting antidepressants -- AMPA receptor potentiators as potential rapid-acting antidepressants -- mGlu2/3 receptor antagonists as rapid-acting antidepressants -- Antidepressant effects of the muscarinic receptor antagonist scopolamine: Clinical and preclinical review.
520 $a This book discusses new candidates for rapid-acting antidepressants, such as (R)-ketamine, (2R,6R)-hydroxynorketamine, scopolamine, mGluR2/3 antagonists and AMPA receptor agonists. There are serious limitations to currently available antidepressants, such as delayed onset and low rates of efficacy. The discovery that a single dose of ketamine, an NMDAR antagonist, can produce rapid antidepressant effects that are sustained has led to new research in this area. In this volume, a variety of novel pharmaceutical treatments are examined. This volume would be useful to both researchers and clinicians who work in the field of pharmacology, specifically CNS drug treatments. Discusses new candidate for rapid-acting antidepressants Provides information for those who work in the field of CNS drugs Ideal for pharmacologists, psychiatrists, and those who want to learn about CNS drugs at the graduate level.
650 0 $a Antidepressants. $3 252255
650 1 4 $a Neurosciences. $3 211508
700 1 $a Hashimoto, Kenji. $3 773594
700 1 $a Manto, Mario. $3 908395
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer Nature eBook
830 0 $a Contemporary clinical neuroscience. $3 712755
856 4 0 $u https://doi.org/10.1007/978-3-030-79790-4
950 $a Biomedical and Life Sciences (SpringerNature-11642)